Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Baxter
Medtronic
Johnson and Johnson
McKinsey

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Claims for Patent: 7,812,215

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,812,215
Title:Methods and protein production using ovomucoid promoters
Abstract: Methods of producing protein using a recombinant ovomucoid gene expression controlling region operably linked to one or more useful amino acid coding sequences.
Inventor(s): Harvey; Alex J. (Athens, GA), Leavitt; Markley C. (Watkinsville, GA), Wang; Youliang (Monroe, GA)
Assignee: Synageva BioPharma Corp. (Waltham, MA)
Application Number:12/313,064
Patent Claims:1. A method comprising isolating a heterologous protein from an egg laid by a transgenic avian wherein the avian contains in its genome a recombinant nucleic acid comprising a nucleotide sequence that is at least 95% identical to a nucleic acid sequence corresponding to the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36 operably linked to a coding sequence encoding the heterologous protein.

2. The method of claim 1 wherein the nucleotide sequence comprises a sequence at least 99% identical to the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36.

3. The method of claim 1 wherein the nucleotide sequence comprises the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36.

4. The method of claim 1 wherein the nucleic acid comprises an attB site.

5. The method of claim 1 wherein the nucleic acid comprises a signal sequence coding region.

6. The method of claim 1 wherein the nucleic acid comprises an IRES.

7. The method of claim 1 wherein the nucleic acid comprises a vector.

8. The method of claim 7 wherein the vector is selected from the group consisting of a plasmid, a viral vector or an artificial chromosome.

9. The method of claim 1 wherein the nucleic acid comprises an artificial chromosome.

10. The method of claim 1 wherein the transgenic avian is selected from the group consisting of chicken and quail.

11. The method of claim 1 wherein the heterologous protein is a therapeutic protein.

12. The method of claim 1 wherein the heterologous protein is an antibody.

13. The method of claim 1 wherein the heterologous protein is a fusion protein.

14. The method of claim 1 wherein the heterologous protein is selected from the group consisting of erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), CTLA4-Fc, interferon, interferon alpha, interferon beta FSH, and beta glucocerebrosidase.

15. The method of claim 1 wherein the heterologous protein is selected from the group consisting of MAb directed against t-lymphocyte antigen CD3, MAb directed against TAG-72, tumor-associated glycoprotein, MAb or MAb fragments directed against platelet surface receptor GPII(b) and/or III(a), MAb fragment or MAb directed against tumor-associated antigen CA125, MAb or MAb fragment directed against human CEA (carcinoembryonic antigen), MAb fragment or MAb directed against human cardiac myosin MAb fragment or MAb directed against tumor surface antigen PSMA, MAb fragments or MAb directed against HMW-MAA, MAb fragment or MAb directed against carcinoma-associated antigen, MAb fragments or MAb directed against NCA 90, MAb directed against CD20 antigen found on surface of B lymphocytes, MAb directed against the alpha chain of the IL2 receptor, MAb directed against TNF-alpha, MAb directed against an epitope on the surface of respiratory, syncytial virus, MAb directed against HER 2 (human epidermal growth factor receptor 2), MAb directed against cytokeratin tumor-associated antigen, anti-CTLA4, dornase-alpha DNAse, TNF-alpha, IL-2-diptheria toxin fusion protein that targets cells displaying a surface IL-2 receptor, TNFR-IgG fragment fusion protein, enbrel, laronidase, teriparatide and parathyroid hormone derivatives.

16. A method comprising isolating a heterologous protein from egg white produced by a transgenic avian wherein the genome of the avian contains a recombinant nucleic acid comprising a nucleotide sequence that is at least 95% identical to a nucleic acid sequence corresponding to the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36 operably linked to a heterologous coding sequence and the amino acid sequence encoded by the heterologous coding sequence is produced in an oviduct cell and is isolated from the egg white.

17. The method of claim 16 wherein the nucleotide sequence comprises a sequence at least 99% identical to the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36.

18. The method of claim 16 wherein the nucleotide sequence comprises the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36.

19. The method of claim 16 wherein the oviduct cell is a tubular gland cell.

20. The method of claim 16 wherein the heterologous coding sequence encodes at least one of a light chain and a heavy chain of an antibody.

21. The method of claim 16 wherein the heterologous coding sequence encodes an antibody selected from the group consisting of IgG, IgA, TgD, IgM and IgE.

22. The method of claim 16 wherein the transgenic avian is selected from the group consisting of chicken and quail.

23. A method comprising isolating a heterologous protein from an egg of a transgenic chicken wherein the genome of the transgenic chicken contains a nucleic acid comprising a nucleotide sequence that is at least 95% identical to a nucleic acid sequence corresponding to the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36 operably linked to a heterologous coding sequence, the amino acid sequence encoded by the heterologous coding sequence being produced in an oviduct cell and packaged into the egg laid by the chicken.

24. The method of claim 23 wherein the nucleotide sequence comprises a sequence at least 99% identical to the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36.

25. The method of claim 23 wherein the nucleotide sequence comprises the sequence of about 34,473 to about 36,248 of SEQ ID NO: 36.

26. The method of claim 23 wherein the heterologous protein is a fusion protein.

27. The method of claim 23 wherein the heterologous protein is a therapeutic protein.

28. The method of claim 27 wherein the therapeutic protein is a fusion protein.

29. The method of claim 23 wherein the heterologous protein is selected from the group consisting of erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), CTLA4-Fc, interferon, interferon alpha, interferon beta, FSH, an antibody and beta glucocerebrosidase.

30. The method of claim 23 wherein the heterologous protein is selected from the group consisting of MAb directed against t-lymphocyte antigen CD3, MAb directed against TAG-72, tumor-associated glycoprotein, MAb or MAb fragments directed against platelet surface receptor GPII(b) and/or III(a), MAb fragment or MAb directed against tumor-associated antigen CA125, MAb or MAb fragment directed against human CEA (carcinoembryonic antigen), MAb fragment or MAb directed against human cardiac myosin, MAb fragment or MAb directed against tumor surface antigen PSMA, MAb fragments or MAb directed against HMW-MAA, MAb fragment or MAb directed against carcinoma-associated antigen, MAb fragments or MAb directed against NCA 90, MAb directed against CD20 antigen found on surface of B lymphocytes, MAb directed against the alpha chain of the IL2 receptor, MAb directed against TNF-alpha, MAb directed against an epitope on the surface of respiratory, syncytial virus, MAb directed against HER 2 (human epidermal growth factor receptor 2), MAb directed against cytokeratin tumor-associated antigen, anti-CTLA4, dornase-alpha DNAse, TNF-alpha, diptheria toxin fusion protein that targets cells displaying a surface IL-2 receptor, TNFR-IgG fragment fusion protein, enbrel, laronidase, teriparatide and parathyroid hormone derivatives.

Details for Patent 7,812,215

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 1998-11-02 ⤷  Try it Free 2021-11-30
Immunex Corporation ENBREL etanercept For Injection 103795 1999-05-27 ⤷  Try it Free 2021-11-30
Immunex Corporation ENBREL etanercept Injection 103795 2004-09-27 ⤷  Try it Free 2021-11-30
Immunex Corporation ENBREL etanercept Injection 103795 2007-02-01 ⤷  Try it Free 2021-11-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Dow
Express Scripts
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.